Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...
GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...
Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...
At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), AASLD President Grace L. Su, MD, of the University of Michigan in Ann Arbor, highlighted ...
Semaglutide, the popular weight loss and diabetes drug, now has the green light to treat moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). If you have the condition and are ...
The last time I spoke about Madrigal Pharmaceuticals (MDGL), it was with respect to a Seeking Alpha article entitled "Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results